You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨多項利好疊加,和譽拉昇升超15%
格隆匯 10-30 11:50
多項利好消息疊加刺激,和譽-B(2256.HK)今日盤中拉昇一度升超15%至3港元,股價創7月底以來新高。和譽今日公吿,將在2023年結締組織腫瘤學會“( CTOS”)年會上發表Pimicotinib (ABSK021)的兩項重大臨牀研究進展。和譽10月27日公吿,公司新一代EGFR-Exon20ins抑制劑ABSK112獲中國藥監局(NMPA)的IND批准,即將開展針對非小細胞肺癌(NSCLC)的國內首次人體I期臨牀試驗。ABSK112之前已獲美國食品藥品管理局(FDA)臨牀研究許可,I期研究將在中美兩地同步開展。和譽醫藥10月24日宣佈,公司在2023年歐洲腫瘤學會(ESMO)年會上公佈了兩項自主研發創新小分子候選藥物的重要臨牀試驗研究成果,分別為FGFR4抑制劑Irpagratinib(ABSK011)在晚期肝細胞癌患者和口服小分子PD-L1抑制劑ABSK043在晚期實體瘤患者的首次人體試驗臨牀數據。兩項研究成果均為同靶點中國公司自研候選藥物首次在國際大會上發佈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account